NCT03151772终止早期 1 期
Drug Level and Investigation of Novel Substances Indicated Downstream Effect in Glioblastoma
Sahlgrenska University Hospital, Sweden1 个研究点 分布在 1 个国家目标入组 3 人开始时间: 2018年1月29日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- Bioavailabilty of metformin
研究概览
简要总结
Neuro-oncological trials may fail due to the drug never getting to the intended target (i.e. within the tumor micro environment). Also, changes' occurring in tumor cells when removed from patients and grown in-vitro is another limiting factor influencing the clinical success.
Important questions are therefore:
- Does the drug get there?
- Does the drug do what it is intended to do?
To improve chances of clinical success there is a need for rational and intelligent selection of potential drugs in future trials. This is an initiative for analyzing tumor concentration of preoperative administered repurposed drugs
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subjects must fulfill all the following inclusion criteria to be eligible for participation in the study, unless otherwise specified:
- •A suspected glioblastoma (based on MRI) or recurrent glioblastoma undergoing surgical resection.
- •Elective surgical indication
- •Age 18 years or older.
- •Karnofsky performance status of 60 - 100 (see attachment 3).
- •Not receiving another experimental treatment for glioblastoma at the moment of inclusion.
- •Able to take oral medications.
- •No known allergy to substance
- •Absolute neutrophil count ≥ 1,500/mcL and platelets ≥ 100,000/mcL
排除标准
- •Other likely diagnosis than glioblastoma based on MRI.
- •Pregnant and/or breastfeeding.
- •Women of childbearing potential who do not have a negative pregnancy test (not older than 14 days) before inclusion.
- •History of active liver disease, including chronic active hepatitis, viral hepatitis (hepatitis B, C and CMV), cholestatic jaundice of any etiology or toxic hepatitis or inadequate hepatic function, defined as baseline ASAT and ALAT > 1.5 X upper institutional limit and/or bilirubin > 1.5 X upper institutional limit.
- •Suspected significant raised intracranial pressure or other indication for emergent surgery
- •Unfit for participation for any other reason judged by the including physician.
- •Specific additional exclusions criteria for disulfiram
- •History of uncontrolled hypertension (i.e. systolic BP > 180 mmHg) and a diagnosis of congestive heart failure
- •History of psychiatric conditions (e.g. depression, psychosis, schizophrenia) or dementia.
- •History of Wilson's disease or family member with Wilson's disease (unless excluded as a carrier by genetic test).
- •History of hemochromatosis or family member with hemochromatosis (unless excluded as a carrier by genetic test).
- •Nickel hypersensitivity (disulfiram mobilize nickel causing a brief increase in nickel concentrations before excretion. The initial increase may lead to hepatitis and predisposed patients).7
- •Need for metronidazole, warfarin and/or theophylline medication (the metabolism may be influenced by disulfiram).
- •Patients who are taking medications metabolized by cytochrome P450 2E1, including chlorzoxazone or halothane and its derivatives (phenytoin, phenobarbital, chlordiazepoxide, imipramine, diazepam, isoniazid, metronidazole, warfarin, amitriptyline within 14 days prior to the first dose of disulfiram. Of note, lorazepam and oxazepam are not affected by the P450 system and are not contraindicated with disulfiram).
- •Addiction to alcohol or drugs. Alcohol must be avoided.
- •Serum/plasma copper and serum ceruloplasmin outside institutional limits. a. However increased levels are seen together with ongoing acute phase reaction as determined by elevated C-reactive protein (ceruloplasmin is elevated as part of the same process) it is possible to retest after normalization of C-reactive protein.
- •Specific additional exclusions criteria for metformin
- •Diabetic patients or other patients where treating physician and/or anesthesiologist consider may have an increased risk for lactic acidosis per- and postoperatively
- •Known renal failure, renal risk factors (including single kidney, donor kidney, polycystic kidneys) or estimated glomerular filtration rate below 80 ml/min.
- •Congestive heart failure
- •Scheduled diagnostic work-up where contrast medium containing iodine is indicated
- •Concomitant use of NSAIDs (risk of renal injury)
- •Risk of dehydration judged by the treating physician (e.g. when symptoms include vomiting)
- •Alcohol must be avoidance during treatment (increased risk of lactic acidosis)
- •Treatment with diuretics as they may increase risk of lactic acidosis.
研究组 & 干预措施
Disulfiram
Experimental
Disulfiram 200 mg twice daily and copper 2,5 mg once daily. For bioavailability purpose only, treatment is withdrawn postoperatively
干预措施: Disulfiram (Drug)
Metformin
Experimental
Metformin 850 mg x 3 daily. For bioavailability purpose only, treatment is withdrawn postoperatively
干预措施: Metformin (Drug)
结局指标
主要结局
Bioavailabilty of metformin
时间窗: At time of surgery
Concentration of metformin available in glioblastoma compared to blood
Bioavailabilty disulfiram
时间窗: At time of surgery
Concentration of disulifram-copper complex available in glioblastoma compared to blood
次要结局
未报告次要终点
研究者
Asgeir S. Jakola
Associate professor, neurosurgeon
Sahlgrenska University Hospital, Sweden
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Bosutinib in Adult Patients With Recurrent GlioblastomaGlioblastomaNCT01331291Massachusetts General Hospital36
招募中
不适用
Study of a novel route of brain targeted drug delivery in human volunteersew route of brain targeted drug delivery using diazepamSLCTR/2007/003one
已完成
3 期
Therapy Based on Stage of Disease and Risk Assessment in Treating Children With NeuroblastomaNeuroblastomaNCT00002802Children's Hospital Medical Center, Cincinnati500
已完成
1 期
CED of MTX110 Newly Diagnosed Diffuse Midline GliomasDiffuse Intrinsic Pontine GliomaDiffuse Pontine and Thalamic GliomasDiffuse Midline GliomaNCT04264143Luca Szalontay9
尚未招募
不适用
Intracellular drug measurements to predict toxicity in high-dose methotrexate therapy in leukaemia and centralnervous system lymphoma.leukaemia and central nervous system lymphomaacute leukemie en centraal zenuwstelsel lymfoomNL-OMON24644Erasmus Medical Center60